ASTHMA EXACERBATION IN CHILDREN : A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnas.v9i2.1533Keywords:
Airflow retriction, Asthma, Children, Corticosteroids, ExacerbationAbstract
According to the definition provided by the Global Initiative for Asthma (GINA), asthma is a chronic inflammatory illness of the airways. This disorder involves the participation of a large number of cells, most notably mast cells, eosinophils, and T lymphocytes. People who are susceptible to the condition have frequent episodes of wheezing, chest tightness, shortness of breath, and coughing, typically late at night or first thing in the morning. These symptoms are typically related to extensive but variable airway blockage, which is at least partially reversible both on its own and with treatment. This obstruction can occur either spontaneously or as a result of treatment. A hyperreactive response of the airways to a variety of stimuli has also been linked to the inflammation. Wheezing is one of the most common symptoms. It is characterized by a high-pitched, whistling musical sound that is produced by turbulence in the airflow. The wheezing heard on the patient's dying breath is the least severe type. Wheezing does not occur during the most severe episodes due to the restriction of airflow that is connected with the narrowing of the airways and the tiredness of the respiratory muscles. A beta2 agonist, azithromycin, inhaled corticosteroids, and antimuscarinic may be recommended to patients under the age of 18 who are experiencing acute exacerbations of their asthma.
References
Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143–78.
Lougheed MD, Lemière C, Dell SD, Ducharme FM, FitzGerald JM, Leigh R, et al. Canadian Thoracic Society Asthma Management Continuum–2010 Consensus Summary for children six years of age and over, and adults. Can Respir J. 2010;17(1):15–24.
Akinbami LJ, Simon AE, Rossen LM. Changing trends in asthma prevalence among children. Pediatrics. 2016;137(1).
Fuchs O, Bahmer T, Rabe KF, von Mutius E. Asthma transition from childhood into adulthood. Lancet Respir Med. 2017;5(3):224–34.
Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol. 2011;128(6):1165–74.
Trivedi M, Denton E. Asthma in children and adults—what are the differences and what can they tell us about asthma? Front Pediatr. 2019;7:256.
Licari A, Manti S, Castagnoli R, Parisi GF, Salpietro C, Leonardi S, et al. Targeted therapy for severe asthma in children and adolescents: current and future perspectives. Pediatr Drugs. 2019;21:215–37.
Licari A, Manti S, Castagnoli R, Marseglia A, Foiadelli T, Brambilla I, et al. Immunomodulation in pediatric asthma. Front Pediatr. 2019;7:289.
Iramain R, Castro-Rodriguez JA, Jara A, Cardozo L, Bogado N, Morinigo R, et al. Salbutamol and ipratropium by inhaler is superior to nebulizer in children with severe acute asthma exacerbation: Randomized clinical trial. Pediatr Pulmonol. 2019 Apr;54(4):372–7.
Papi A, Chipps BE, Beasley R, Panettieri RAJ, Israel E, Cooper M, et al. Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. N Engl J Med. 2022 Jun;386(22):2071–83.
Ghimire JJ, Jat KR, Sankar J, Lodha R, Iyer VK, Gautam H, et al. Azithromycin for Poorly Controlled Asthma in Children: A Randomized Controlled Trial. Chest. 2022 Jun;161(6):1456–64.
Leversha AM, Campanella SG, Aickin RP, Asher MI. Costs and effectiveness of spacer versus nebulizer in young children with moderate and severe acute asthma. J Pediatr. 2000;136(4):497–502.
Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659–68.
Wongwaree S, Daengsuwan T. Comparison efficacy of randomized nebulized magnesium sulfate and ipratropium bromide/fenoterol in children with moderate to severe asthma exacerbation. Asian Pacific J allergy Immunol. 2022 Mar;40(1):31–8.
Amir Najim Abood HA, Al-Musawi ZM, Hussein AM, Hameed RM. Effects of nebulized budesonide plus salbutamol and nebulized salbutamol monotherapy on mild to moderate acute exacerbation of asthma in children: A comparative study. J Pak Med Assoc. 2021 Dec;71(Suppl 9)(12):S29–34.
Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. Glob Strateg Asthma Manag Prev. 2019;
Fishman JA, Grippi MA, Kotloff RM, et al. Fishman’s Pulmonary Disease and Disorders Fifth Edition. New York: Elsevier Saunder; 2016.
World Health Organization (WHO). Asthma. Geneva; 2019.
World Health Organization (WHO). The Global Asthma Report. Geneva; 2018.
Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short?acting beta 2?agonists for initial treatment of acute asthma in children. Cochrane Database Syst Rev. 2013;(8).
Delgado A, Chou KJ, Silver EJ, Crain EF. Nebulizers vs metered-dose inhalers with spacers for bronchodilator therapy to treat wheezing in children aged 2 to 24 months in a pediatric emergency department. Arch Pediatr Adolesc Med. 2003;157(1):76–80.
Chen A, Zeng G, Chen R, Zhan J, Sun L, Huang S, et al. Effects of nebulized high-dose budesonide on moderate-to-severe acute exacerbation of asthma in children: a randomized, double-blind, placebo-controlled study. Respirology. 2013 Nov;18 Suppl 3:47–52.
Powell C, Kolamunnage-Dona R, Lowe J, Boland A, Petrou S, Doull I, et al. Magnesium sulphate in acute severe asthma in children (MAGNETIC): a randomised, placebo-controlled trial. Lancet Respir Med. 2013;1(4):301–8.
Smith D, Du Rand I, Addy CL, Collyns T, Hart SP, Mitchelmore PJ, et al. British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. Thorax [Internet]. 2020 May 1;75(5):370 LP – 404. Available from: http://thorax.bmj.com/content/75/5/370.abstract
Bruntol L, Dandan R, Knollmann B. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. Philadelphia: Mc Graw Hill Education; 2018.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Journal of Advance Research in Applied Science
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Terms & Condition
Submission -
Author can submit the manuscript through our online submission process or email us at the designated email id in contact details.
The other mode of submission not accepted than online and email.
Before submission please read the submission guidelines.
NN Publication accepts only article submitted in pdf/doc/docx/rtf file format. Another format except given file formats will no be considered .
Author will be responsible for the error mistakes in the submission files. The minor changes can be done without any cost after publication. But for major changes NN Publication may charges you the editing charges.
Publication (Online) -
The online publication is scheduled on last date of every month, but it can be delayed by 24 to 48 hours due to editorial process if huge number of articles comes to publish in single issue.
Automatic notificatation email will be sent to the all users on publication of an issue, so its author’s duty to check their email inbox or SPAM folder to get this notification.
After publication of article author can not withdraw their article.
If editor’s found any issue after publication of article then the NN Publication have the authority to remove the article from online website.
No refund will be provided after online publication of article.
Publication (Print) -
The print copy publication are sent as per the author’s request after 2 weeks of online publication of that issue.
NN Publication will ship the article by India Post and provide the consignment number on dispatch of print copy.
NN Publication follows all the guidelines of delivery provided by IndiaPost and hence not responsible for delay in delivery due to any kind of reasons.
Refund of hard copy will not be provided after dispatch or print of the journal.
NN Publication will be responsible for raise a complain if there is any issue occurs in delivery, but still will not be responsible for providing the refund.
NN Publication will be responsible to resend the print copy only and only if the print copy is lost or print copy is damaged in delivery / or there is delay more than 6 months.
According to India Post the delivery should be completed with in 1-3 weeks after dispatch of articles.
Privacy Policy-
NN Publicationl uses the email ids of authors and editors and readers for sending editorial or publication notification only, we do not reveal or sell the email ids to any other website or company.
